Skip to main content
. 2011 Apr 8;70(7):1208–1215. doi: 10.1136/ard.2011.153023

Figure 1.

Figure 1

Clinical responses to infliximab therapy in patients with rheumatoid arthritis at week 54. The European League Against Rheumatism response criteria and disease activity were measured by the disease activity score in 28 joints (DAS28)–C-reactive protein (CRP) using the last observation carried forward method. Disease activity was defined as high disease activity, DAS28–CRP greater than 4.1; moderate disease activity, 2.7 or greater to 4.1 or less; low disease activity, 2.3 or greater to less than 2.7; and DAS28–CRP remission, less than 2.3. *p<0.05 versus the 3 mg/kg groups.